{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T07:02:34Z","timestamp":1760598154968,"version":"3.41.2"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T00:00:00Z","timestamp":1647475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background\/Aims<\/jats:title><jats:p>Chimeric antigen receptor (CAR) T cells for refractory or relapsed (r\/r) B-cell acute lymphoblastic leukemia (ALL) patients have shown promising clinical effectiveness. However, the factors impacting the clinical response of CAR-T therapy have not been fully elucidated. We here aimed to identify the independent factors of CAR-T treatment response and construct the models for predicting the complete remission (CR) and minimal residual disease (MRD)-negative CR in r\/r B-ALL patients after CAR-T cell infusion.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Univariate and multivariate logistic regression analyses were conducted to identify the independent factors of CR and MRD-negative CR. The predictive models for the probability of remission were constructed based on the identified independent factors. Discrimination and calibration of the established models were assessed by receiver operating characteristic (ROC) curves and calibration plots, respectively. The predictive models were further integrated and validated in the internal series. Moreover, the prognostic value of the integration risk model was also confirmed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The predictive model for CR was formulated by the number of white blood cells (WBC), central neural system (CNS) leukemia, <jats:italic>TP53<\/jats:italic> mutation, bone marrow blasts, and CAR-T cell generation while the model for MRD-negative CR was formulated by disease status, bone marrow blasts, and infusion strategy. The ROC curves and calibration plots of the two models displayed great discrimination and calibration ability. Patients and infusions were divided into different risk groups according to the integration model. High-risk groups showed significant lower CR and MRD-negative CR rates in both the training and validation sets (<jats:italic>p<\/jats:italic> &amp;lt; 0.01). Furthermore, low-risk patients exhibited improved overall survival (OS) (log-rank <jats:italic>p<\/jats:italic> &amp;lt; 0.01), higher 6-month event-free survival (EFS) rate (<jats:italic>p<\/jats:italic> &amp;lt; 0.01), and lower relapse rate after the allogeneic hematopoietic stem cell transplantation (allo-HSCT) following CAR-T cell infusion (<jats:italic>p<\/jats:italic> = 0.06).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>We have established predictive models for treatment response estimation of CAR-T therapy. Our models also provided new clinical insights for the accurate diagnosis and targeted treatment of r\/r B-ALL.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2022.858590","type":"journal-article","created":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T05:26:49Z","timestamp":1647494809000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Identification of the Predictive Models for the Treatment Response of Refractory\/Relapsed B-Cell ALL Patients Receiving CAR-T Therapy"],"prefix":"10.3389","volume":"13","author":[{"given":"Jingxian","family":"Gu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sining","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiping","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingya","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liqing","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiying","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miao","family":"Miao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suning","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengli","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengming","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaming","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Depei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaowen","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-399287","article-title":"Outcome of Relapsed Adult Lymphoblastic Leukemia Depends on Response to Salvage Chemotherapy, Prognostic Factors, and Performance of Stem Cell Transplantation","volume":"120","author":"G\u00f6kbuget","year":"2012","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-08-234492","article-title":"The Myth of the Second Remission of Acute Leukemia in the Adult","volume":"121","author":"Forman","year":"2013","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab Versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23919","article-title":"Outcome of Adults With Acute Lymphocytic Leukemia After Second Salvage Therapy","volume":"113","author":"O'Brien","year":"2008","journal-title":"Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-348540","article-title":"Safety and Persistence of Adoptively Transferred Autologous CD19-Targeted T Cells in Patients With Relapsed or Chemotherapy Refractory B-Cell Leukemias","volume":"118","author":"Brentjens","year":"2011","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-11-1920","article-title":"The Future Is Now: Chimeric Antigen Receptors as New Targeted Therapies for Childhood Cancer","volume":"18","author":"Lee","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(14)61403-3","article-title":"T Cells Expressing CD19 Chimeric Antigen Receptors for Acute Lymphoblastic Leukaemia in Children and Young Adults: A Phase 1 Dose-Escalation Trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1172\/jci85309","article-title":"CD19 CAR-T Cells of Defined CD4+:CD8+ Composition in Adult B Cell ALL Patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-To-Treat Leukemia Remission by CD19 CAR T Cells of Defined Formulation and Dose in Children and Young Adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults With B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-Term Follow-Up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.07.005","article-title":"Engineering CAR-T Cells for Next-Generation Cancer Therapy","volume":"38","author":"Hong","year":"2020","journal-title":"Cancer Cell"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(19)30823-x","article-title":"CAR T Cells: Continuation in a Revolution of Immunotherapy","volume":"21","author":"Singh","year":"2020","journal-title":"Lancet Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1200\/jco.18.02079","article-title":"Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Multiply Relapsed or Refractory Adult Large B-Cell Lymphoma","volume":"71","author":"Lin","year":"2019","journal-title":"J Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-021-03009-z","article-title":"Factors Associated With Treatment Response to CD19 CAR-T Therapy Among a Large Cohort of B Cell Acute Lymphoblastic Leukemia","author":"Zhang","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B18","doi-asserted-by":"publisher","first-page":"5928","DOI":"10.1038\/s41467-020-19774-x","article-title":"Influence of Patient Characteristics on Chimeric Antigen Receptor T Cell Therapy in B-Cell Acute Lymphoblastic Leukemia","volume":"11","author":"An","year":"2020","journal-title":"Nat Commun"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-11-883710","article-title":"Factors Associated With Durable EFS in Adult B-Cell ALL Patients Achieving MRD-Negative CR After CD19 CAR T-Cell Therapy","volume":"133","author":"Hay","year":"2019","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0184-6","article-title":"Mechanisms of Resistance to CAR T Cell Therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-786129","article-title":"Cellular Kinetics of CTL019 in Relapsed\/Refractory B-Cell Acute Lymphoblastic Leukemia and Chronic Lymphocytic Leukemia","volume":"130","author":"Mueller","year":"2017","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and Management of AML in Adults: 2017 ELN Recommendations From an International Expert Panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/anae.14329","article-title":"The Association of Time of Emergency Surgery - Day, Evening or Night - With Postoperative 30-Day Hospital Mortality","volume":"73","author":"Tessler","year":"2018","journal-title":"Anaesthesia"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-01140-6","article-title":"Donor-Derived Anti-CD19 CAR T Cells Compared With Donor Lymphocyte Infusion for Recurrent B-ALL After Allogeneic Hematopoietic Stem Cell Transplantation","volume":"56","author":"Hua","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2682","article-title":"Donor Origin CAR19 T Cell Infusion for B-ALL Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation","volume":"37","author":"Yang","year":"2019","journal-title":"Hematol Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current Concepts in the Diagnosis and Management of Cytokine Release Syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated With Immune Effector Cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01056-6","article-title":"Donor-Derived CD19 CAR-T Cell Therapy of Relapse of CD19-Positive B-ALL Post Allotransplant","volume":"35","author":"Zhang","year":"2021","journal-title":"Leukemia"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001466","article-title":"Efficacy and Safety of Anti-CD19 CAR T-Cell Therapy in 110 Patients With B-Cell Acute Lymphoblastic Leukemia With High-Risk Features","volume":"4","author":"Zhang","year":"2020","journal-title":"Blood Adv"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.263","article-title":"The Impact of TP53 Mutations and TP53 Deletions on Survival Varies Between AML, ALL, MDS and CLL: An Analysis of 3307 Cases","volume":"31","author":"Stengel","year":"2017","journal-title":"Leukemia"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-02-558833","article-title":"TP53 Mutations Occur in 15.7% of ALL and Are Associated With MYC-Rearrangement, Low Hypodiploidy, and a Poor Prognosis","volume":"124","author":"Stengel","year":"2014","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1172\/jci87366","article-title":"Dual CD19 and CD123 Targeting Prevents Antigen-Loss Relapses After CD19-Directed Immunotherapies","volume":"126","author":"Ruella","year":"2016","journal-title":"J Clin Invest"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-111856","article-title":"Sequential CD19-And CD22-CART Cell Therapies for Relapsed B-Cell Acute Lymphoblastic Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation","volume":"132","author":"Liu","year":"2018","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.2147\/ott.s235882","article-title":"Sequential Infusion of Anti-CD22 and Anti-CD19 Chimeric Antigen Receptor T Cells for a Pediatric Ph-Like B-ALL Patient That Relapsed After CART-Cell and Haplo-HSCT Therapy: A Case Report and Review of Literature","volume":"13","author":"Hua","year":"2020","journal-title":"Onco Targets Ther"},{"key":"B35","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1182\/blood.2019000017","article-title":"Efficacy and Safety of CAR19\/22 T-Cell Cocktail Therapy in Patients With Refractory\/Relapsed B-Cell Malignancies","volume":"135","author":"Wang","year":"2020","journal-title":"Blood"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.858590\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T05:26:51Z","timestamp":1647494811000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.858590\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,17]]},"references-count":35,"alternative-id":["10.3389\/fimmu.2022.858590"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.858590","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2022,3,17]]},"article-number":"858590"}}